Literature DB >> 15097881

massive peripapillary subretinal neovascularization: an indication for submacular surgery.

Peter J Kertes1.   

Abstract

PURPOSE: To describe the course and outcome of three consecutive patients with massive peripapillary subretinal neovascularization secondary to ocular histoplasmosis syndrome managed with submacular surgery.
METHODS: Three eyes of three consecutive patients with progressive and massive peripapillary subretinal neovascularization secondary to ocular histoplasmosis syndrome were treated with submacular surgery and followed up for a mean of 41 months (range, 11-59 months). The main outcomes were surgical complications, visual acuity, and subretinal membrane recurrence.
RESULTS: Visual acuity improved in each patient from counting fingers, 20/25, and 20/400 preoperatively to 20/50, 20/20, and 20/20, respectively, at the last follow-up visit. With respect to complications, Patient 3 was found to have an operculated retinal tear approximately 1 month postoperatively, which was successfully treated with argon laser retinopexy. There were no cases of visually significant cataract, rhegmatogenous retinal detachment, or recurrent choroidal neovascularization in any of the operated eyes during the period of follow-up.
CONCLUSIONS: Submacular surgery proved safe and beneficial in this small series of young patients with massive peripapillary subretinal neovascularization secondary to ocular histoplasmosis syndrome and should be considered in this relatively uncommon clinical presentation.

Entities:  

Mesh:

Year:  2004        PMID: 15097881     DOI: 10.1097/00006982-200404000-00005

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  4 in total

1.  Surgical treatment of peripapillary choroidal neovascularisation.

Authors:  Susanne Binder
Journal:  Br J Ophthalmol       Date:  2007-08       Impact factor: 4.638

2.  Surgical treatment of peripapillary choroidal neovascularisation.

Authors:  S Aisenbrey; F Gelisken; P Szurman; K U Bartz-Schmidt
Journal:  Br J Ophthalmol       Date:  2007-02-14       Impact factor: 4.638

Review 3.  Recent developments in age-related macular degeneration: a review.

Authors:  Waseem M Al-Zamil; Sanaa A Yassin
Journal:  Clin Interv Aging       Date:  2017-08-22       Impact factor: 4.458

Review 4.  Potential Therapeutic Benefit of NAD+ Supplementation for Glaucoma and Age-Related Macular Degeneration.

Authors:  Gloria Cimaglia; Marcela Votruba; James E Morgan; Helder André; Pete A Williams
Journal:  Nutrients       Date:  2020-09-19       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.